These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 19426116)

  • 1. Costimulatory blockade with belatacept in clinical and experimental transplantation - a review.
    Emamaullee J; Toso C; Merani S; Shapiro AM
    Expert Opin Biol Ther; 2009 Jun; 9(6):789-96. PubMed ID: 19426116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Belatacept in clinical and experimental transplantation - progress and promise.
    Rangel EB
    Drugs Today (Barc); 2010 Apr; 46(4):235-42. PubMed ID: 20502720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costimulation targeting therapies in organ transplantation.
    Gandhi AM; Fazli U; Rodina V; Qazi YA
    Curr Opin Organ Transplant; 2008 Dec; 13(6):622-6. PubMed ID: 19060553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Belatacept: a novel biologic for maintenance immunosuppression after renal transplantation.
    Martin ST; Tichy EM; Gabardi S
    Pharmacotherapy; 2011 Apr; 31(4):394-407. PubMed ID: 21449628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Belatacept: a new era of immunosuppression?
    El-Charabaty E; Geara AS; Ting C; El-Sayegh S; Azzi J
    Expert Rev Clin Immunol; 2012 Aug; 8(6):527-36. PubMed ID: 22992146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Costimulation blockade in autoimmunity and transplantation.
    Vincenti F
    J Allergy Clin Immunol; 2008 Feb; 121(2):299-306; quiz 307-8. PubMed ID: 18269922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological agents in kidney transplantation: belatacept is entering the field.
    Wéclawiak H; Kamar N; Ould-Mohamed A; Cardeau-Desangles I; Rostaing L
    Expert Opin Biol Ther; 2010 Oct; 10(10):1501-8. PubMed ID: 20726688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges and opportunities in targeting the costimulation pathway in solid organ transplantation.
    Wojciechowski D; Vincenti F
    Semin Immunol; 2011 Jun; 23(3):157-64. PubMed ID: 21856169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Belatacept : a new biological agent for maintenance immunosuppression in kidney transplantation.
    Arora S; Tangirala B; Osadchuk L; Sureshkumar KK
    Expert Opin Biol Ther; 2012 Jul; 12(7):965-79. PubMed ID: 22564126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of belatacept-mediated costimulation blockade through evaluation of CD80/86-receptor saturation.
    Latek R; Fleener C; Lamian V; Kulbokas E; Davis PM; Suchard SJ; Curran M; Vincenti F; Townsend R
    Transplantation; 2009 Mar; 87(6):926-33. PubMed ID: 19300198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Profile of belatacept and its potential role in prevention of graft rejection following renal transplantation.
    Gupta G; Womer KL
    Drug Des Devel Ther; 2010 Dec; 4():375-82. PubMed ID: 21151624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A network meta-analysis of the efficacy of belatacept, cyclosporine and tacrolimus for immunosuppression therapy in adult renal transplant recipients.
    Goring SM; Levy AR; Ghement I; Kalsekar A; Eyawo O; L'Italien GJ; Kasiske B
    Curr Med Res Opin; 2014 Aug; 30(8):1473-87. PubMed ID: 24628478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Late onset Pneumocystis pneumonia in renal transplantation after long-term immunosuppression with belatacept.
    Haidinger M; Hecking M; Memarsadeghi M; Weichhart T; Werzowa J; Hörl WH; Säemann MD
    Transpl Infect Dis; 2009 Apr; 11(2):171-4. PubMed ID: 19210692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Effect of ASP2409, a Novel CD86-Selective Variant of CTLA4-Ig, on Renal Allograft Rejection in Nonhuman Primates.
    Oshima S; Karrer EE; Kawato Y; Maeda M; Fukahori H; Tsujimoto S; Hirose J; Nakamura K; Marui T; Takamura F; Noto T; Chapin SJ; Fujii Y; Neighbors M; Viswanathan S; Devens BH; Higashi Y
    Transplantation; 2016 Dec; 100(12):2611-2620. PubMed ID: 27861289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T cell costimulation: a rational target in the therapeutic armamentarium for autoimmune diseases and transplantation.
    Vincenti F; Luggen M
    Annu Rev Med; 2007; 58():347-58. PubMed ID: 17020493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Belatacept utilization recommendations: an expert position.
    Grinyó JM; Budde K; Citterio F; Charpentier B
    Expert Opin Drug Saf; 2013 Jan; 12(1):111-22. PubMed ID: 23206310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Belatacept in kidney transplantation.
    Satyananda V; Shapiro R
    Curr Opin Organ Transplant; 2014 Dec; 19(6):573-7. PubMed ID: 25333833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Belatacept: a novel immunosuppressive agent for kidney transplant recipients.
    Charpentier B
    Expert Rev Clin Immunol; 2012 Nov; 8(8):719-28. PubMed ID: 23167683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of posttransplant lymphoproliferative disorder associated with use of belatacept.
    Martin ST; Powell JT; Patel M; Tsapepas D
    Am J Health Syst Pharm; 2013 Nov; 70(22):1977-83. PubMed ID: 24173007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Belatacept: a new biologic and its role in kidney transplantation.
    Su VC; Harrison J; Rogers C; Ensom MH
    Ann Pharmacother; 2012 Jan; 46(1):57-67. PubMed ID: 22215686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.